Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO).

Next Previous
X
Search
Trial Profile

Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tacrolimus (Primary) ; Tacrolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms STRATO
  • Sponsors Veloxis Pharmaceuticals

    • Most Recent Events

    • 21 Sep 2015 Results published in Clinical Transplantation, according to Veloxis Pharmaceuticals media release.
    • 20 May 2013 Status changed from active, no longer recruiting to completed, as reported by a Veloxis media release.
    • 20 May 2013 Final results presented at the 13th American Transplant Congress, according to a Veloxis media relase.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top